Role of Pyroptosis in Respiratory Diseases and its Therapeutic Potential

Jingjing Liu1−3, Guoqing Fan1−3, Ningning Tao4, Tieying Sun1,2

1Department of Respiratory Medicine and Critical Care, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Graduate School of Peking Union Medical College, Beijing, People’s Republic of China; 3The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, People’s Republic of China; 4Department of Respiratory Medicine and Critical Care, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People’s Republic of China

Correspondence: Tieying Sun, Department of Respiratory Medicine and Critical Care, Beijing Hospital, Dongcheng District, Beijing, 100730, People’s Republic of China, Tel +86 15153169108, Email suntieying@126.com

Abstract: Pyroptosis is an inflammatory type of regulated cell death that is dependent on inflammasome activation and downstream proteases such as caspase-1 or caspase 4/5/11. The main executors are gasdermins, which have an inherent pore-forming function on the membrane and release inflammatory cytokines, such as interleukin (IL)-1β, IL-18 and high mobility group box 1. Emerging evidence demonstrates that pyroptosis is involved in the pathogenesis of various pulmonary diseases. In this review, we mainly discuss the biological mechanisms of pyroptosis, explore the relationship between pyroptosis and respiratory diseases, and discuss emerging therapeutic strategies for respiratory diseases.

Keywords: pyroptosis, pulmonary disease, caspase-1, caspase-4/5/11, gasdermins

Introduction

Pyroptosis is a newly discovered type of regulated cell death that was first described in Salmonella-infected macrophages and dendritic cells.1 The morphological characteristics of pyroptosis which are distinguishable from necroptosis include cell membrane pore formation, cytomembrane fracture, cellular swelling, chromatin condensation, and increased inflammatory cytokine production. However, in contrast to apoptosis, the integrity of the mitochondria is maintained, and pyroptosis has no effect on the release of cytochrome C.1−3

Pyroptosis was initially reported to occur in innate immune cells, such as macrophages, dendritic cells, and neutrophils. However, recent studies have demonstrated that pyroptosis can also occur in epithelial cells, endothelial cells, keratinocytes, and neurons.4

Pyroptosis was initially described as an inflammatory type of regulated cell death mediated by caspase-1 which belongs to the inflammatory caspase family and is activated by inflammasome.5 An inflammasome is an intracellular multi-protein compound, which mainly includes the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) and PYHIN protein families.6 The inflammasomes can be activated by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs).7 Bioactive caspase-1 can process gasderminD (GSDMD) into a GSDMD N-terminal (GSDMD-NT) fragment and cleave pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18, eventually leading to canonical pyroptosis and the release many inflammatory cytokines.7

Lipopolysaccharides (LPS) from gram-negative bacteria can directly bind to caspase-4/5/11 independent of caspase-1 to induce pyroptosis, and this is described as the non-canonical pyroptosis pathway.8 In 2015, it was discovered that GSDMD is an executor of pyroptosis, N terminal of GSDMD can form pores on the plasma membrane, thereby releasing many inflammatory cytokines, pro-fibrotic cytokines, and cell contents.9,10 Notably, other gasdermin family members (such as GSDMA, GSDMB, GSDMC, and GSDME) have been increasingly involved in cell membrane pore formation and pyroptosis induction.11−14 Therefore, the Nomenclature Committee on Cell Death modified the definition of pyroptosis, and it is now described as a cell death dependent on the gasdermin family’s participation in membrane pore formation.15
Pyroptosis is involved in the development of various diseases, such as cancer, and autoimmune, metabolic, and nervous system diseases.\textsuperscript{16–19} Emerging evidence has confirmed that Dermatophagoides farinae (Der f1)-induced pyroptosis in human bronchial epithelia contributes to the development of asthma.\textsuperscript{20} In addition, inflammasome-mediated pyroptosis participates in the pathogenesis of pulmonary infections, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD).\textsuperscript{21–24} Therefore, the role of pyroptosis in pulmonary diseases, particularly, in the development of novel diagnostic and therapeutic methods to manage these diseases, has become a research focus.

This review highlights the signaling pathway and inhibitors involved in pyroptosis and the relationship between pyroptosis and pulmonary diseases. It also discusses potential therapeutic targets related to pyroptosis in pulmonary diseases.

**Molecular Mechanisms of Pyroptosis**

**Components of the Inflammasome**

The inflammasome is an intracellular multi-protein compound consisting of a sensor protein (for example, pattern recognition receptors [PRRs]), apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) and a caspase-1 family protease.\textsuperscript{25} PRRs can identify PAMPs or DAMPs and include the NLR family (NLRP3, and NLR family caspase recruitment domain [CARD] containing proteins, such as NLRC1, NLRC4, and NLRC6) localized in the cytoplasm, which is present within the plasma membrane or lysosomal organelles and PYHIN protein family including absent in melanoma (AIM2).\textsuperscript{26,27} NLR proteins consist of C-terminal leucine-rich repeats (LRRs), a central NOD/NACHT, and an N-terminal CARD or pyrin domain (PYD). The NOD/NACHT domain is shared by the NLR family and its downstream pathway is activated by adenosine triphosphate (ATP)-dependent oligomerization. LRRs are associated with ligand sensing and autoregulation, and the CARD and PYD domains interact with the downstream signals.\textsuperscript{28} Of note, NLRP3 has been identified as a crucial NLR family member, which recognizes PAMPs (such as bacteria, viruses, and fungi) or DAMPs (e.g. ATP and uric acid).\textsuperscript{29} Other NLR family members include NLRP1, which is activated by the anthrax lethal toxin;\textsuperscript{30} NLRC4, which is activated by cytosolic bacterial flagellin, such as that of Salmonella;\textsuperscript{31} and NLRP6, which is activated by microbes, such as Porphyromonas gingivalis.\textsuperscript{32} AIM2 proteins typically contain a DNA-binding HIN-200 domain and a PYD-signaling domain, which specifically recognize cytoplasmic double-stranded DNA.\textsuperscript{27} Pyrin is encoded by the MEFV gene, which has four functional domains; PYD, and the zinc finger, coiled coil, and B30.2/SPRY domains. It specifically recognizes RhoA guanosine triphosphatase inactivation induced by pathogens.\textsuperscript{32} ASC is an essential intermediate protein that combines sensor proteins (NLRs and AIM2) and caspase-1, whereas NLRC4 is an exception. NLRC4 activates caspase-1 by directly recruiting pro-caspase-1.\textsuperscript{33}

Canonical inflammasome activation requires two independent steps. Taking the activation of the NLRP3 inflammasome as an example, the first step is priming, which is induced by the Toll-like receptor (TLR)/myeloid differentiation primary response 88 (MyD88)-nuclear factor kappa B (NF-κB) signaling pathway to upregulate the transcription of NLRP3, pro-IL-1β and pro-IL-18.\textsuperscript{6,7,25,34} The second step involves formation and modification of the NLRP3 inflammasome. There are three classic activation pathways of the NLRP3 inflammasome. (i) potassium efflux,\textsuperscript{35} which is a mutual pathway for the assembly of the NLRP3 inflammasome which promotes the interaction between NEK7-NLRP3,\textsuperscript{36,37} (ii) lysosomes damage\textsuperscript{35,38} (iii) the generation of mitochondrial reactive oxygen species (ROS).\textsuperscript{35} Mitochondrial ROS promotes the dissociation of thioredoxin from thioredoxin-interacting protein (TXNIP). Subsequently, TXNIP can bind to NLRP3 and trigger the activation of the NLRP3 inflammasome by stimulating the recruitment of ASC and caspase-1.\textsuperscript{39} Pro-caspase-1 is activated by inflammasomes to form bioactive caspase-1. Caspase-1 can cut the precursors of downstream inflammatory cytokines (such as pro IL-1β and pro IL-18) and turn them into bioactive cytokines (IL-1β and IL-18).

Non-canonical NLRP3 inflammasome activation has been recently discovered, and it is associated with potassium efflux.\textsuperscript{40–42} Potassium efflux via GSDMD pores in caspase-4/5/11-mediated non-classical pyroptosis is essential for NLRP3 inflammasome activation.\textsuperscript{41} Another study showed that LPS-induced caspase-11 activation triggered cleavage of the pannexin-1 channel, which promoted the release of ATP. ATP triggers P2X7, a purinoreceptor, to form a channel for potassium efflux, and subsequently, the NLRP3 inflammasome is activated.\textsuperscript{42} Emerging evidence has demonstrated that
caspase-8 is associated with NLRP3 inflammasome activation by promoting the formation of ASC and activation of caspase-1, and is also possibly related to potassium efflux.\(^43\)

**Caspase Family Proteases**

Caspase-1/4/5 and caspase-1/11 expressed in humans and mice, respectively, are the main caspase family proteases associated with pyroptosis.\(^44\) Caspase-1 exists as an inert precursor in the cytoplasm, which can be activated by inflammasomes and can promote apoptosis and mediate the canonical pyroptosis pathway.\(^45\) Caspase-1 proteolytically cleaves the precursor pro-IL-1β/pro-IL-18 to generate mature IL-1β/IL-18 and cleaves GSDMD into a 31kD N-terminal and a 22kD C-terminal. GSDMD-NT forms pores on the cell membrane, thus, inducing pyroptosis and releasing IL-1β, IL-18, IL-1α and high mobility group box 1 (HMGB1).\(^46\)

Caspase-4/5/11 are involved in the non-canonical pyroptosis pathway. CARD in caspase-4/5/11 recognizes LPS lipid A and induces the oligomerization of the caspases. Activated caspase-4/5/11 cleave GSDMD and release the GSDMD-NT fragment to induce cell membrane pore formation, release IL-1α and HMGB1, and lead to pyroptosis.\(^9,44\) However, caspase-4/5/11-mediated pyroptosis has no effect on the processing of IL-1β and IL-18. Interestingly, caspase-4/5/11 triggers non-canonical NLRP3 inflammasome activation to promote IL-1β and IL-18 secretion.\(^9\)

An increasing number of caspase family members have been found to play a role in pyroptosis. Caspase-3 was previously known as an executor of apoptosis, and emerging evidence has demonstrated that activated caspase-3 cleaves GSDME, thereby releasing the GSDME N-terminal and triggering pyroptosis.\(^14,47,48\) Caspase-3 is activated by caspase-8 through the death receptor pathway and can also be activated by caspase-9 via the mitochondrial apoptotic pathway.\(^48,49\)

Various death stimuli or viral infections can result in permeabilization of the mitochondrial outer membrane, leading to the release of cytochrome C, which promotes the activation of caspase-9 which then cleaves caspase-3.\(^48\) Emerging evidence suggests that caspase-1/3/7 cleave GSDME to generate GSDME-N terminal and induce pyroptosis in teleosts, and GSDME is cleaved by caspase-1 with high efficiency and by caspase-3 and 7 with less efficiency.\(^50\) Furthermore, caspase-8 is considered a molecular switch for pyroptosis.\(^51–53\) Previous studies have demonstrated that caspase-8 triggers the formation of ASC specks, activation of caspase-1, and subsequent activation of the NLRP3 inflammasome, leading to pyroptosis in bone marrow-derived macrophages (BMDMs) and intestinal epithelial cells.\(^51\) Sarhan et al found that caspase-8 could cleave both GSDMD and GSDME, resulting in pyroptosis in murine macrophages during *Yersinia* infections.\(^52\) A recent study claimed that caspase-8 directly cleaves GSDMD to trigger pyroptosis, which provides the host defense against *Yersinia* infections.\(^53\) Therefore, caspase-3/7/8 can also mediate pyroptosis.

**Gasdermins: Executioners of Pyroptosis**

Gasdermins are a family of pore-forming effector proteins that increase membrane permeabilization and induce pyroptosis. The gasdermin family is encoded by six paralogous genes in humans: *GSDMA, GSDMB, GSDMC, GSDMD, GSDME,* and *PJVK,* and nine genes in mice: *Gsdma 1–3, Gsdmc 1–4, Gsdme* and *pjvk.*\(^10\) The gasdermin family is composed of a cytotoxic N-terminal domain and a C-terminal inhibitory domain, and is linked by a long loop in the middle.\(^10\) This structure is shared by all gasdermin family members except for PJVK, which has a truncated C-terminal domain.\(^54\)

GSDMD is an executor of pyroptosis.\(^9\) Activated caspase-1/4/5/11 acts on the aspartic acid site on the circle to cleave GSDMD into two fragments: a 31-kDa GSDMD-NT fragment with an inherent pore-forming function and a 22-kDa GSDMD C-terminal (GSDMD-CT) fragment, which has an autoinhibitory role in the GSDMD-NT fragment.\(^9,10\) The GSDMD-NT fragment can target, using cardiolipin and phosphoinositides, the membrane to destroy its structure by forming pores with a diameter of 10–14nm and inducing pyroptosis.\(^55\) Recent studies found that caspase-8 can cleave GSDMD into GSDMD-NT and GSDMD-CT fragments and induce pyroptosis.\(^43,52,53\) The pathway leading to GSDMD activation extends beyond the caspase family, and emerging evidence has demonstrated that neutrophil elastase can cleave GSDMD in active neutrophils.\(^56,57\) Although the site cleaved by neutrophil elastase is different from that of caspases, GSDMD still generates a fragment with pore-forming functions.\(^57\)

An increasing number of gasdermin family members have been found to play a role in pyroptosis. GSDME cleaved by caspase-3 can induce pyroptosis.\(^47,48\) Rogers et al revealed that caspase-3 cleaved GSDME at Asp270 and divided into
N-terminal and C-terminal fragments. The N-terminus of GSDME has the same function as GSDMD-NT, which has intrinsic pore-forming activity and induces pyroptosis in apoptotic cells, but is not scavenged. Wang et al claimed that GSDME cleaved by caspase-3 can switch from apoptosis, induced by tumor necrosis factor alpha (TNF-α) or chemotherapy drugs, to pyroptosis, and GSDME-/- mice are protected from chemotherapy-induced tissue damage. A study of pyroptosis in teleosts suggested that GSDME, which is the only gasdermin family member present in teleosts, triggers pyroptosis, and GSDME is cleaved by caspase-1/3/7, all of which occur at the FEVD site in the linker region of GSDME.

GSDMA acts as an effector of epithelial pyroptosis during Streptococcus pyogenes infections, and the cysteine protease SpeB of Streptococcus pyogenes cleaves GSDMA in the linker region after Gln246 and generates N-terminus of GSDMA, triggering pyroptosis.

In 2020, Feng et al claimed that GSDMB was cleaved by lymphocyte-derived granzyme A to induce pyroptosis in natural killer cells and cytotoxic T lymphocytes. GSDMB is highly expressed in various tissues, especially in the digestive tract epithelia, including derived tumors. GSDMB cleaved by granzyme A-induced pyroptosis promotes tumor clearance in mice, and may enhance anti-tumor immunity.

Hou et al revealed that the N-terminus of GSDMC also induces pyroptosis, and GSDMC is cleaved by caspase-8. Phosphorylated signal transducer and activator of transcription 3 interacts with programmed death ligand 1 and promotes its nuclear translocation, which upregulates GSDMC transcription under hypoxic conditions. GSDMC is cleaved by caspase-8 under TNF-α treatment, thereby switching from apoptosis to pyroptosis and facilitating tumor necrosis.

Although the N-terminus of GSDMA, GSDMB, GSDMC, and GSDME also drive cells to undergo pyroptosis, GSDMD is still the best characterized executor of pyroptosis.

Canonical (Caspase-1-Mediated) Pyroptosis Pathway
The canonical pyroptosis signaling pathway is triggered by inflammasomes, mainly the NLR family and pyrin protein families. Inflammasomes can be activated by different stimulants, such as PAMPs or DAMPs. Caspase-1 is triggered by the inflammasome and pro-IL-1β/pro-IL-18 is converted to IL-1β/IL-18 via caspase-1. Simultaneously, caspase-1 cleaves GSDMD and releases the GSDMD-NT. The GSDMD-NT fragment forms pores on the cytomembrane and promotes the secretion of the inflammatory cytokines, IL-1β, IL-18, IL-1α and HMGB1, resulting in plasma membrane rupture, cellular swelling, and eventually cell death (pyroptosis) (Figure 1).

Non-Canonical (Caspase-4/5/11-Mediated) Pyroptosis Pathway
The non-canonical pyroptosis pathway was initially thought to be mediated by caspase-4/5/11. LPS from gram-negative bacteria can access the cell cytoplasm via CD14/TLR4/MD2 receptor-mediated endocytosis or bacterial outer membrane vesicles and bind directly to caspase-4/5/11. The CARD in caspase-4/5/11 recognizes lipid A, which is the most conserved region in LPS, and induces oligomerization of caspases. Activated caspase-4/5/11 cleaves GSDMD into a GSDMD-NT fragment to induce cell membrane pore formation and initiate pyroptosis. However, caspase-4/5/11-mediated pyroptosis cannot release IL-1β and IL-18, in contrast to the caspase-1-mediated classical pyroptosis pathway. Interestingly, caspase-4/5/11 triggers non-canonical NLRP3 inflammasome activation through a cell-intrinsic process to promote IL-1β and IL-18 secretion (Figure 1).

Other Pyroptosis Pathways
In 2017, it was discovered that the caspase-3/GSDME pathway induces pyroptosis. GSDME, cleaved by caspase-3 during apoptosis, mediates the switch to pyroptosis. Furthermore, caspase-3/GSDME-mediated pyroptosis is involved in chemotherapy-induced tissue damage, providing a new target for the treatment of cancer. A recent study revealed that cleavage of GSDME by caspase-1/3/7 is the only pathway that induces pyroptosis in teleosts.

The mechanism underlying caspase-8-mediated pyroptosis is complex. Caspase-8 induces pyroptosis by activating the NLRP3 inflammasome. Another report claims that caspase-8 cleaves GSDMD and releases GSDMD-NT to trigger pyroptosis. Interestingly, a recent study has demonstrated that caspase-8 could cleave both GSDMD and GSDME and release their N-terminal fragments, thus inducing pyroptosis. The cleavage of GSDMA by the cysteine protease SpeB triggers pyroptosis during Streptococcus pyogenes infections. GSDMB cleaved by granzyme A as an effector of
pyroptosis mainly occurs in natural killer cells and cytotoxic T lymphocytes and is involved in the pathogenesis of gastrointestinal tumors. Furthermore, caspase-8/GSDMC mediates a non-classical pyroptosis pathway in cancer cells, resulting in tumor necrosis (Figure 1).

Role of Pyroptosis in Respiratory Diseases
Emerging evidence has revealed that pyroptosis is a key process for various diseases, including autoimmune diseases (eg cryptothermal protein-associated cycle syndrome, rheumatoid arthritis, and Crohn’s disease), nervous system diseases (eg Alzheimer’s disease and Parkinson’s disease), metabolic diseases (eg gout and type II diabetes), atherosclerosis, and cancer (eg colon cancer, breast cancer and melanoma). The role of pyroptosis in respiratory diseases has received considerable attention. Pyroptosis is relevant to the pathogenesis of respiratory diseases, whether as a positive or negative regulator. Therefore, we illuminate the role of pyroptosis in several respiratory diseases, including COPD, asthma, acute respiratory distress syndrome (ARDS), pulmonary fibrosis, lung cancer, and pulmonary infection.

COPD
COPD is a heterogeneous disease characterized by irreversible airflow obstruction, involving chronic inflammation of the small airways and lung parenchyma, which causes small airway fibrosis and emphysema. COPD is predicted to become the third leading cause of death and the fifth leading cause of economic burdens worldwide. Despite intense research

Figure 1 The mechanism of pyroptosis. Pyroptosis involves canonical, non-canonical, and other pathways. NLRP3 inflammasome activation requires DAMPs or PAMPs to trigger the NF-κB-mediated upregulation of NLRP3, pro-IL-1β and pro-IL-18. The formation and modification of NLRP3 inflammasomes by potassium efflux, the generation of reactive oxygen species (ROS), and cathepsin B released by lysosomal damage. Caspase-1 is triggered by the inflammasome and pro-IL-1β/IL-1β is converted to IL-1β/IL-18 via caspase-1. Simultaneously, caspase-1 cleaves GSDMD and releases the GSDMD-NT. The GSDMD-NT fragment forms pores on the cytomembrane and promotes the secretion of the inflammatory cytokines, IL-1β and IL-18, resulting in plasma membrane rupture, cellular swelling, and eventually pyroptosis. LPS from gram-negative bacteria can access the cell cytoplasm via TLR4 receptor-mediated endocytosis and bind directly to caspase-4/5/11. Activated caspase-4/5/11 cleaves GSDMD into a GSDMD-NT fragment to induce cell membrane pore formation and initiate pyroptosis. This process can also cause NLRP3 activation by potassium efflux via nonselective pores. The cysteine protease (SpeB) from group A Streptococcus (GAP) can cleave GSDMA, triggering pyroptosis. The cleavage of GSDMA by the cysteine protease (SpeB), triggers pyroptosis during Streptococcus pyogenes infections. Active caspase-3 cleave GSDME and release GSDME-NT, thereby triggers pyroptosis. Caspase-8 can cleave GSDMD, GSDME, and GSDMC, to trigger pyroptosis.
efforts focused on the pathogenesis and therapy of COPD, the pathogenesis of COPD has not been fully elucidated, and only a few therapies can lower mortality rates and exacerbations in patients with COPD. Infection, exposure to toxic particles, air pollution and cigarette smoke (CS) are the major causes of COPD.

CS is a major cause of COPD worldwide. Increased inflammasome activation, ASC speck accumulation, and IL-1β expression are observed in the lungs of patients with COPD, as well as in experimental models including murine models of COPD. Furthermore, the NLRP3 inflammasome was upregulated in an in vitro model of COPD exacerbation, and it may serve as a novel biomarker in the diagnosis of COPD exacerbation and as a new target for therapies. However, another report revealed that NLRP3 inflammasome had no correlation with the severity of stable COPD patients, possibly due to the increased expression of the inflammasome and inflammasome inhibitory molecules IL-37 and NALP7. These studies indicate that inflammasome activation and expression of IL-1β may play important roles in the pathogenesis of COPD, whereas the role of pyroptosis in the pathogenesis of COPD has been poorly studied.

A recent study indicated that CS-induced pyroptosis occurs via the ROS/NLRP3 inflammasome pathway in bronchial epithelial cells. Moreover, the caspase-1 inhibitor, VX-765, can inhibit pyroptosis in bronchial epithelial cells, and the ROS inhibitor, N-acetyl-L-cysteine, inhibits the activation of NLRP3 inflammasome and production of IL-1β and IL-18. Emerging evidence has revealed that triggering receptor expressed on myeloid cells (TREM-1) is highly expressed in COPD mice and promotes lung injury and inflammation via activation of NLRP3 inflammasome-mediated pyroptosis. Furthermore, inhibition of TREM-1 notably improved the injury in lung tissues of COPD mice and suppressed the activation of NLRP3 inflammasome and pyroptosis, which may provide a novel therapeutic target for COPD treatment. Some studies found that inhibition of pyroptosis could ameliorate CS-induced COPD. For example, (-)-Epicatechin ameliorated CS-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome-mediated pyroptosis in rats with COPD. Exosomes derived from adipose-derived stem cells could inhibit alveolar macrophages pyroptosis, thereby attenuated lung injury and inflammation caused by CS.

Asthma

Asthma is a common chronic inflammatory airway disease that results from the interaction between inflammatory cells (eg mast cells, eosinophils, neutrophils, and T cells) and inflammatory cytokines. It is characterized by airway hyper-responsiveness, airway inflammation, airway remodeling, and reversible airflow limitation due to occupational or environmental exposure to microbes, industrial products, and other allergens. In patients with asthma, clumps of epithelial cells in the sputum and increased epithelial cells in bronchoalveolar lavage fluid (BALF) indicate that epithelial cell sloughing is a pathological characteristic of asthma. Furthermore, recent studies have demonstrated pyroptosis in experimental models of asthma and in cell lines. Therefore, epithelial cell pyroptosis may represent a pathogenic mechanism contributing to inflammatory injury of airway epithelia. Toluene diisocyanate-induced pyroptosis in bronchial epithelial cells is mediated by the NLRP3 inflammasome, resulting in cytomebrane fracture and release of inflammatory mediators. It is observed in asthmatic mice; it enhances airway sensitivity and responsiveness, and causes continuous airway inflammation. MCC950, a specific NLRP3 inhibitor, can inhibit pyroptosis in bronchial epithelial cells and asthmatic mice and slow the progression of asthma. Der f1-induced pyroptosis in bronchial epithelial cells through the NLRP3 inflammasome pathway plays a key role in asthma pathogenesis and airway remodeling, and a caspase-1 inhibitor (Z-YVAD-FMK) inhibits the release of IL-1β and subsequently, Der f1-induced pyroptosis. Simultaneously, a new study suggests that PARK2, a Parkinson’s disease-associated gene that is involved in house dust mite-induced pyroptosis in BEAS-2B cells negatively regulates NLRP3 protein via ubiquitination; therefore, PARK2 is a negative upstream regulator of the NLRP3 inflammasome. In addition, a recent study has shown that pyroptosis plays an important role in promoting airway remodeling in the pathogenesis of asthma.

GSDMB is highly expressed in differentiated bronchial epithelial cells, and cleavage of GSDMB by caspase-1 induces pyroptosis. Furthermore, multiple coding variants in the GSDMB gene in the 17q21 locus are associated with reduced asthma risk, and the splicing variant, rs11078928, abolishes the pyroptotic activity of GSDMB. This implicates GSDMB-mediated epithelial cell pyroptosis in the pathogenesis of asthma and provides a potential asthma therapy targeting pyroptosis. These results confirm that targeting inflammasomes and pyroptosis can provide a new direction for the treatment of asthma.
Acute Lung Injury (ALI)/ARDS

ALI/ARDS as acute diffuse pulmonary inflammation is characterized by hypoxemia, diffuse alveolar injury, and acute respiratory failure, leading to an increase in pulmonary microvascular endothelial permeability, pulmonary edema, and the reduction of lung tissue involved in ventilation.\textsuperscript{89} Its high mortality rate has a significant impact on public health.\textsuperscript{90} The inflammasome pathway and its downstream cytokines play critical roles in ARDS development.\textsuperscript{91} IL-18 and caspase-1 promote the development of ARDS. Moreover, IL-18 is increased in circulation, which correlates with disease severity and mortality in the MICU.\textsuperscript{91} Notably, pyroptosis in alveolar macrophages plays an essential role in the pathogenesis of ALI/ARDS.\textsuperscript{92–94} LPS recognized by TLR4 not only activates the NLRP3 inflammasome and subsequently promotes the release of IL-1\(\beta\), but also upregulates IL-1R1 expression on alveolar macrophage surface through the MyD88/NF-\(\kappa\)B dependent pathway. The upregulated expression of IL-1R enables the sensitization of alveolar macrophages to IL-1\(\beta\) and causes pyroptosis. In summary, the LPS-TLR4 pathway triggers alveolar macrophages and augments ALI/ARDS via secondary upregulation of IL-1\(\beta\)-IL-1R1 signaling.\textsuperscript{92} NLRP3 inflammasome-mediated pyroptosis in macrophages may also play a crucial role in the pathogenesis of ALI/ARDS via the p38 MAPK signal pathway and blocking this pathway can ameliorate ALI by inhibiting macrophage pyroptosis and converting pyroptosis to apoptosis.\textsuperscript{93} Interestingly, extracellular histones promote alveolar macrophages pyroptosis through the NLRP3/caspase-1 pathway, which in turn aggravates lung inflammation in ARDS.\textsuperscript{94} Phospholipid scramblase 4 (PLSCR4) is a member of single-pass transmembrane proteins that can transfer phospholipids (PS) from the inside to the outside of the cell membrane in a Ca\(^{2+}\)-dependent manner.\textsuperscript{95} PLSCR4 can reduce the binding of the pyroptosis executive protein GSDMD-NT to PS and the formation of pyroptosis pores, thereby reducing the degree of pyroptosis. Furthermore, PLSCR4 is mainly regulated by P62.\textsuperscript{96} Recently, Kerr et al. have shown that extracellular vesicle-mediated inflammasome and pyroptosis play a role in traumatic brain injury (TBI)-induced ALI model in mice and patients, and ASC can be used as an excellent biomarker for the diagnosis of TBI-induced ALI. In addition, anti-ASC treatment significantly reduces inflammasome activation and TBI-induced ALI.\textsuperscript{96,97} Therefore, these studies provide new therapeutic strategies for controlling ALI/ARDS. Interestingly, NecroX-5, an inhibitor of necrosis, alleviated lung inflammation in murine models with ALI/ARDS by inhibiting the NF-\(\kappa\)B signaling pathway and inhibiting activation of the NLRP3 inflammasome. We speculate that there is crosstalk between necrosis and pyroptosis.\textsuperscript{98} Therefore, a comprehensive investigation of pyroptosis and its correlation with other cell death pathways would provide a novel therapeutic strategy for the treatment of ARDS.

Pulmonary Fibrosis

Pulmonary fibrosis is characterized by progressive and irreversible destruction of the lungs, leading to progressive decline in lung function. The mechanism underlying pulmonary fibrosis is not yet fully understood. Asbestosis, silica, CS, particulate matter, and bleomycin (BLM) are associated with pulmonary fibrosis.\textsuperscript{99} Many studies indicate that inflammasomes, such as the NLRP3 and AIM2 inflammasomes, which are tightly associated with pyroptosis, play critical roles in the pathogenesis of pulmonary fibrosis. Several published studies have shown that the NLRP3 inflammasome is involved in lung fibrosis in both experimental models and patients. The NLRP3 inflammasome promotes the release of IL-1\(\beta\), which can promote fibroblast-to-myofibroblast differentiation and activate the TGF-\(\beta\)1/Smads signal pathway.\textsuperscript{100–103} NLRP3 inflammasome activation in alveolar epithelial cells promotes myofibroblast differentiation of lung-resident mesenchymal stem cells, and MCC950 attenuates BLM-induced pulmonary fibrosis.\textsuperscript{104} Moreover, a study has confirmed that NLRP3 inflammasome activation in aged mice increases susceptibility to pulmonary fibrosis.\textsuperscript{103} AIM2 inflammasome activation has been found in peripheral blood mononuclear cells (PBMCs) from patients with idiopathic pulmonary fibrosis (IPF), which leads to the activation of caspase-4, which induces the release of IL-1\(\alpha\) responsible for the release of transforming growth factor beta 1 (TGF-\(\beta\)1) from PBMCs.\textsuperscript{105} Reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) participates in the destruction of lysosomes and promotes the production of ROS. ROS production and cathepsin B are directly involved in NLRP3 inflammasome activation. Moreover, N-acetyl-L-cysteine can attenuate NLRP3 inflammasome activation and lung fibrosis.\textsuperscript{106} Treatment targeting NLRP3, AIM2, caspase-1, IL-1\(\beta\), and ROS can effectively alleviate pulmonary fibrosis, which may also serve to inhibit lung injury and fibrosis. Another study found that the activation of NLRP3 inflammasome was impaired in patients with IPF, and the level of IL-18 in the BALF was lower than that in control patients. This may be because the innate immune response of patients with IPF is impaired, including...
While the NLRP3 inflammasome was activated, the levels of NLRP3 and caspase-1 were increased in patients with RA-UIP, and IL-1β and IL-18 were significantly elevated in the BALF and BALF macrophages. Autophagy and NLRP3 inflammasomes are activated in patients with fibrosis and are positively correlated with oxidation in vivo. Angiotensin-II (Ang II) promotes intercellular ROS and NOX4 levels, leading to NLRP3 inflammasome activation and stimulates collagen synthesis through the NLRP3/caspase-1/IL-1β pathway. Furthermore, autophagy suppresses NLRP3 inflammasome activation by eliminating ROS and alleviating mitochondrial dysfunction. Taken together, autophagy alleviates pulmonary fibrosis by regulating NLRP3 inflammasome activation induced by Ang II-mediated via redox balance modulation. NLRP3 inflammasome-mediated pyroptosis in macrophages promotes collagen synthesis and the progression of pulmonary fibrosis in BLM-induced pulmonary fibrosis models, and lycorine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and pyroptosis. Another study reported that bone marrow-derived mesenchymal stem cells can inhibit pyroptosis triggered by NLRP3/caspase-1 in silica-induced pulmonary fibrosis. Emerging studies have shown that AIM2 inflammasome activation and pyroptosis in macrophages are involved in the pathogenesis of radiation-induced pulmonary fibrosis. Andrographolide ameliorated radiation-induced pulmonary fibrosis by inhibiting AIM2 inflammasome-mediated pyroptosis in macrophages, thus, identifying andrographolide as a new potential protective agent against for radiation-induced pulmonary fibrosis. These studies demonstrated that inflammasomes and induced pyroptosis participate in the pathogenesis of pulmonary fibrosis, and would provide new targets for patients with pulmonary fibrosis.

### Pulmonary Infection

Macrophage pyroptosis is a protective mechanism against *Klebsiella pneumoniae* infection and facilitates the clearance of bacteria. Pyroptosis mediated by caspase-11 can promote neutrophil recruitment and bacterial clearance against *K. pneumoniae* infection, and caspase-11 knockout blocks this effect. However, different clinical strains of *K. pneumoniae* have different mechanisms of survival within macrophages. The A28006 strain induced macrophage pyroptosis and high IL-1β production, which is easily cleared; in contrast, the A54970 strain induced high IL-10 production, which inhibited macrophage pyroptosis to evade host defense, resulting in the dissemination of bacteria. Studies on *Salmonella typhimurium* and *Legionella pneumophila* have revealed that bacteria flagellin is an agonist of NLRC4 inflammasome-mediated pyroptosis in macrophages, which restricts bacterial replication in vivo. However, *Salmonella typhimurium* avoids innate immune mechanisms by evading NLRC4 inflammasome-mediated pyroptosis. NLRC4 inflammasome-mediated pyroptosis plays a protective role during *Burkholderia pseudomallei* infection. Knockdown of NLRC4 in mice causes high susceptibility to bacterial infections due to reduced pyroptosis and an increased bacterial burden. Moreover, IL-18 cleaved by the NLRP3 inflammasome protects against *B. pseudomallei* lung infection, due to its ability to increase the production of interferon (IFN-γ), whereas IL-1β is deleterious because of excessive recruitment of neutrophils to the lung. Wang et al analyzed the protective role of the canonical and noncanonical pyroptosis pathways during *B. pseudomallei* infection. Caspase-1 triggers pyroptosis, mainly in infected macrophages, and controls the release of IL-18. In contrast, caspase-11-mediated pyroptosis mainly occurs in infected lung epithelial cells. In summary, pyroptosis is an efficient effector mechanism that restricts bacterial growth and dissemination during *B. pseudomallei* infection. NLRC4 inflammasome-mediated pyroptosis plays different roles during *Pseudomonas aeruginosa* infection, depending on host conditions. Flagella-expressing *P. aeruginosa* can activate the NLRC4 inflammasome and promote the secretion of IL-1β/IL-18 by macrophages in acute *P. aeruginosa* pneumonia, and NLRC4 inflammasome signaling not only impairs bacterial clearance but is also involved in increased mortality. Strategies limiting NLRC4 inflammasome activation have limited the pathological consequences of acute *P. aeruginosa* pulmonary infection. However, NLRC4 inflammasome is failed to activate by clinical isolates of *P. aeruginosa* from chronically infected cystic fibrosis patients during both stable and exacerbation infection, which indicated that *P. aeruginosa*-activated inflammasomes are not involved in cystic fibrosis pulmonary exacerbations. Emerging evidence revealed that neutrophils pyroptosis were essential for host protection during *P. aeruginosa* lung infection in the absence of NOX2. Thus, specifically target neutrophil pyroptosis are likely to be useful for curing highly intractable *P. aeruginosa* infections. *Acinetobacter baumannii*-induced pyroptosis contributes to the lung damage and high mortality in a
Another study claimed that Therefore, GSDMD may be used as an independent GSDME is silenced in most cancer cells due to methylation of the GSDME-mediated pyroptosis promoted Simvastatin inhibited proliferation and metastasis in NSCLC via pyroptosis mediated by the GSDMD knockdown Polyphyllin VI (PPVI) activated the NLRP3 inflammasome and induced the apoptosis-to- Therefore, GSDME-mediated pyroptosis may be conducive to improve the chemotherapy sensitivity of gene. The combination of methylation inhibitors and chemotherapy agents can convert apoptosis into caspase-3/ Paclitaxel and cisplatin, Emerging evidence has revealed that caspase-3/ GSDMD, contributing to cytotoxic T lymphocyte-mediated killing. Emerging evidence has revealed that caspase-3/ GSDME-mediated pyroptosis is involved in the treatment of NSCLC with chemotherapy. Paclitaxel and cisplatin, as representative chemotherapeutic drugs for lung cancer, could induce apoptosis in A549 cells, but caspase-3/GSDME-induced pyroptosis was observed in some dying cells. Furthermore, cisplatin induced higher levels of pyroptosis in A549 cells than paclitaxel did, and GSDME knockdown significantly inhibited cisplatin-induced pyroptosis, which revealed that cisplatin may provide additional advantages in the treatment of lung cancers with high levels of GSDME expression. Another study explored the effect of GSDME-mediated pyroptosis in the treatment of NSCLC with cisplatin and claimed that GSDME-mediated pyroptosis enhances cisplatin sensitivity to NSCLC, and low GSDME expression in tumor tissues indicates a short survival time and high mortality rate after platinum treatment. GSDME-mediated pyroptosis promoted tumor CD3+T cell infiltration via GSDME-NT pores. GSDME is silenced in most cancer cells due to methylation of the GSDME gene. The combination of methylation inhibitors and chemotherapy agents can convert apoptosis into caspase-3/ GSDME-mediated pyroptosis and significantly improve the efficacy of chemotherapy through immune activation by pyroptosis. Therefore, GSDME-mediated pyroptosis may be conducive to improve the chemotherapy sensitivity of lung cancer and may provide a new potential target for the development of lung cancer immunotherapy. miR-556-5p enhances the sensitivity of cisplatin by inducing NLRP3-mediated pyroptosis in cisplatin-resistance NSCLC cells. Long non-coding RNA X-inactive specific transcript (LncRNA-XIST) is an oncogene in various cancers and is aberrantly overexpressed in NSCLC tissues or cell lines, which promotes NSCLC cell proliferation, invasion, and metastasis. Downregulation of LncRNA-XIST can promote ROS production and NLRP3 inflammasome activation to induce pyroptosis. Moreover, miR335 is the downstream target of LncRNA-XIST, and LncRNA-XIST regulates superoxide dismutase 2 (SOD2) levels by targeting miR-335. Taken together, knockdown of LncRNA-XIST suppressed NSCLC development by inducing miR-335/SOD2/ROS-mediated pyroptosis. Xu et al revealed that LncRNA-XIST was upregulated in NSCLC cells previously treated with cisplatin. Interestingly, knockdown of LncRNA-XIST promoted chemosensitivity to cisplatin by inducing pyroptosis in NSCLC cells. Taken together, these findings reveal that pyroptosis may participate in the regulation of chemotherapeutic sensitivity in NSCLC, which provides new therapeutic strategies to overcome chemo-resistance in patients with NSCLC in clinical setting. Additional studies have found that triggering pyroptosis is a novel approach for treating lung cancer. For instance, cucurbitacin B inhibited NSCLC in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis, which supports cucurbitacin B as a potential therapeutic agent for NSCLC. Simvastatin inhibited proliferation and metastasis in NSCLC via pyroptosis mediated by the NLRP3/caspase-1 pathway. Polyphyllin VI (PPVI) activated the NLRP3 inflammasome and induced the apoptosis-to-

Lung Cancer

Lung cancer is the most common cancer and leading cause of cancer-related mortality worldwide. GSDMD expression was increased in non-small cell lung cancer (NSCLC) and was associated with tumor metastasis. Moreover, high GSDMD expression implies a poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma. GSDMD knockdown alleviated tumor proliferation by switching NLRP3/caspase-1-mediated-pyroptosis to apoptosis and suppressing the epidermal growth factor receptor/protein kinase pathway in NSCLC. Therefore, GSDMD may be used as an independent prognostic biomarker for lung adenocarcinoma. Furthermore, GSDMD plays an essential role in tumor immunity through GSDMD, contributing to cytotoxic T lymphocyte-mediated killing. Emerging evidence has revealed that caspase-3/GSDME-mediated pyroptosis is involved in the treatment of NSCLC with chemotherapy. Paclitaxel and cisplatin, as representative chemotherapeutic drugs for lung cancer, could induce apoptosis in A549 cells, but caspase-3/GSDME-induced pyroptosis was observed in some dying cells. Furthermore, cisplatin induced higher levels of pyroptosis in A549 cells than paclitaxel did, and GSDME knockdown significantly inhibited cisplatin-induced pyroptosis, which revealed that cisplatin may provide additional advantages in the treatment of lung cancers with high levels of GSDME expression. Another study explored the effect of GSDME-mediated pyroptosis in the treatment of NSCLC with cisplatin and claimed that GSDME-mediated pyroptosis enhances cisplatin sensitivity to NSCLC, and low GSDME expression in tumor tissues indicates a short survival time and high mortality rate after platinum treatment. GSDME-mediated pyroptosis promoted tumor CD3+T cell infiltration via GSDME-NT pores. GSDME is silenced in most cancer cells due to methylation of the GSDME gene. The combination of methylation inhibitors and chemotherapy agents can convert apoptosis into caspase-3/GSDME-mediated pyroptosis and significantly improve the efficacy of chemotherapy through immune activation by pyroptosis. Therefore, GSDME-mediated pyroptosis may be conducive to improve the chemotherapy sensitivity of lung cancer and may provide a new potential target for the development of lung cancer immunotherapy. miR-556-5p is a small non-coding RNA that is significantly upregulated in patients with cisplatin-resistant NSCLC. Silencing of miR-556-5p enhances the sensitivity of cisplatin by inducing NLRP3-mediated pyroptosis in cisplatin-resistance NSCLC cells. Long non-coding RNA X-inactive specific transcript (LncRNA-XIST) is an oncogene in various cancers and is aberrantly overexpressed in NSCLC tissues or cell lines, which promotes NSCLC cell proliferation, invasion, and metastasis. Downregulation of LncRNA-XIST can promote ROS production and NLRP3 inflammasome activation to induce pyroptosis. Moreover, miR335 is the downstream target of LncRNA-XIST, and LncRNA-XIST regulates superoxide dismutase 2 (SOD2) levels by targeting miR-335. Taken together, knockdown of LncRNA-XIST suppressed NSCLC development by inducing miR-335/SOD2/ROS-mediated pyroptosis. Xu et al revealed that LncRNA-XIST was upregulated in NSCLC cells previously treated with cisplatin. Interestingly, knockdown of LncRNA-XIST promoted chemosensitivity to cisplatin by inducing pyroptosis in NSCLC cells. Taken together, these findings reveal that pyroptosis may participate in the regulation of chemotherapeutic sensitivity in NSCLC, which provides new therapeutic strategies to overcome chemo-resistance in patients with NSCLC in clinical setting. Additional studies have found that triggering pyroptosis is a novel approach for treating lung cancer. For instance, cucurbitacin B inhibited NSCLC in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis, which supports cucurbitacin B as a potential therapeutic agent for NSCLC. Simvastatin inhibited proliferation and metastasis in NSCLC via pyroptosis mediated by the NLRP3/caspase-1 pathway. Polyphyllin VI (PPVI) activated the NLRP3 inflammasome and induced the apoptosis-to-
pyroptosis switch in NSCLC, which supported that PPVI might be a new candidate for the future treatment of NSCLC. L61H10, a heterocyclic ketone derivative exerted anti-tumor effects in NSCLC, mainly through the switch of apoptosis-to-pyroptosis mediated by the NF-κB signaling pathway.

Inhibitors of Pyroptosis

In recent years, great progress has been made in research on the molecules involved in the process of pyroptosis. Herein, we provide a brief introduction to the therapeutic strategies for the inhibition of pyroptosis (Table 1).

Inhibitors of Proinflammatory Caspases

IDN-6556, VX-740 (pralnacasan), and its analog VX-765 are common caspase-1 Inhibitors. VX-740 and VX-765 are peptidomimetic drugs, which both catalyze the active site cysteine residues of caspase-1 by reversible covalent attack. IDN-6556 acts through irreversible covalent modification of catalyzing the active site cysteine residues, thus inhibiting caspase-1 and reducing the release of IL-1β/IL-18. VX-765 and VX-740 were effective in the treatment of RA and osteoarthritis in murine models, and they blocked the release of IL-1β and IL-18. Furthermore, VX765 reversed cognitive impairment and neuroinflammation in mouse models of AD. It reduces the area of myocardial infarction and maintains ventricular function in mice models. To date, three caspase-1 inhibitors (VX-740, VX-765 and IDN-6556) have entered clinical trials for RA, epilepsy, psoriasis, and chronic hepatitis C viral infection; however, IDN-6556 has been withdrawn from clinical trials because of undisclosed reasons. VX-765 was reported to alleviate airway inflammation in the mice models with asthma, and rescued the degree of emphysema in CS-exposed mice.

NLRP3 Inflammasome Inhibitors

MCC950, a diarylsulfonylurea-containing compound, is the best-studied NLRP3 inhibitor; it is highly specific and selective. It inhibits NLRP3 inflammasome activation and IL-1β production by blocking ASC oligomerization, which is specific for the NLRP3 inflammasome, and does not affect the activation of other inflammasomes. A recent study

| Agents       | Target(s) | Potential Mechanism                                                                 | References |
|--------------|-----------|-------------------------------------------------------------------------------------|------------|
| VX-740       | Caspase-1 | Reversible covalent attack of catalyzing the active site cysteine residues of caspase-1 resulting in inhibiting caspase-1 and the release of IL-1β/IL-18 | [136,137]  |
| VX-765       |           |                                                                                     |            |
| IDN-6556     | Caspase-1 | Irreversible covalent modification of catalyzing the active site cysteine residues of caspase-1 blocking in inhibiting caspase-1 and the release of IL-1β/IL-18 | [34,135]   |
| MCC950       | NLRP3     | Directly interact with the NACHT domain and block ATP hydrolysis resulted in blocking the canonical and non-canonical NLRP3 inflammasome activation | [143,144]  |
| Glyburide    | NLRP3     | Act downstream of P2X7 inhibiting the aggregation of ASC                               | [145]      |
| Glyburide    | NLRP3     | (indirectly)                                                                        |            |
| ICI100       | ASC       | Prevent ASC oligomerization and prevent recruitment of ASC into the inflammasome complex | [146]      |
| Punicalagin  | GSDMD     | Block plasma membrane fluidity and interfere with correct GSDMD-NT insertion into the cell membrane | [148]      |
| Necrosulfonamide | GSDMD | Directly binding to GSDMD through Cys191 and inhibits the formation of pores via GSDMD-NT fragments on the plasma membrane | [150]      |
| LDC7559      | GSDMD     | Remain unknown                                                                       | [56]       |
| DMF          | GSDMD, GSDME | DMF reacts with GSDMD and GSDME at critical cysteine residues to form S-(2-succinyl)-cysteine, thereby inhibits pyroptosis. | [151]      |
| Disulfiram   | GSDMD     | Disulfiram covalently modifies human Cys191/mouse Cys192 in GSDMD to block pore formation of GSDMD | [152]      |
revealed that MCC950 directly interacts with the NACHT domain and blocks ATP hydrolysis and can rescue airway remodeling and alleviate neutrophil airway inflammation in asthma murine models.\textsuperscript{21,144} Another study reported that MCC950 inhibits pyroptosis in human bronchial epithelial cells mediated by the NLRP3 inflammasome.\textsuperscript{85}

Glyburide, a sulfonylurea drug, has recently been found to indirectly inhibit the activation of the NLRP3 inflammasome. Research has shown that glyburide inhibits PAMPs and DAMPs induced by NLRP3 inflammasome activation, while inhibiting the activation of caspase-1 and secretion of IL-1β, which acts downstream of P2X7, inhibiting the aggregation of ASC.\textsuperscript{145}

IC100, a monoclonal antibody targeting ASC, acts extracellularly to prevent ASC oligomerization and recruitment into the inflammasome complex.\textsuperscript{146} A study found that IC100 inhibits the immune inflammatory response that drives the development and progression of experimental autoimmune encephalomyelitis.\textsuperscript{146} Anti-ASC treatment significantly suppresses inflammasome activation and TBI-induced ALI.\textsuperscript{96,97}

**Gasdermin Inhibitors**

Punicalagin was the first compound to block pyroptosis and IL-1β release.\textsuperscript{147,148} Punicalagin blocks plasma membrane fluidity and interferes with correct GSDMD-NT insertion into the cell membrane.\textsuperscript{148} Moreover, a recent study suggested that punicalagin affects the activation of NLR4 and NLRP1 inflammasomes, possibly by affecting membrane fluidity and blocking the delivery of inflammasome activators.\textsuperscript{149} In contrast, punicalagin has no effect on the generation of GSDMD-NT and activation of NLRP3 and AIM2 inflammasome.\textsuperscript{148}

Necrosulfonamide is a cysteine-reactive drug that inhibits pyroptosis in murine macrophages and human monocytes.\textsuperscript{150} It directly binds to GSDMD through Cys191 and inhibits the formation of pores via GSDMD-NT fragments, thereby inhibiting the release of IL-1β. Necrosulfonamide is highly specific for GSDMD and has no effect on inflammasome activation and pyroptosis induced by the GSDME-NT terminal.\textsuperscript{150}

LDC7559, a NET formation inhibitor based on the pyrazolo-oxazepane scaffold, binds to GSDMD and blocks neutrophil elastase-dependent pyroptosis in human neutrophils; however, its mechanism is unclear.\textsuperscript{56}

Dimethyl fumarate (DMF) is an intermediate in the citric acid cycle, and is currently used in the treatment of multiple sclerosis. DMF reacts with GSDMD at critical cysteine residues to form S-(2-succinyl)-cysteine. GSDMD succination prevents activation of inflammatory caspases and inhibits pyroptosis. DMF protects against familial Mediterranean fever and experimental autoimmune encephalomyelitis in mice by inhibiting pyroptosis.\textsuperscript{151} Furthermore, DMF inhibits GSDME-mediated pyroptosis through GSDME succination.\textsuperscript{151}

Disulfiram, an inhibitor of acetaldehyde dehydrogenase, has been approved for the treatment of alcohol addiction. A recent study revealed that disulfiram covalently modified human Cys191/mouse Cys192 in GSDMD to block pore formation of GSDMD. Interestingly, disulfiram had no effect on the processing of GSDMD and IL-1β but abrogates GSDMD pore-formation.\textsuperscript{152}

**Potential Medicines for Pyroptosis in Respiratory Diseases**

Cucurbitacin B is a natural triterpenoid derived from *Cucurbitaceae* plants. A previous study found that cucurbitacin B could directly interact with TLR4 to activate the NLRP3 inflammasome and increase mitochondrial ROS production to induce pyroptosis, subsequently inhibiting NSCLC in vivo and in vitro.\textsuperscript{131} Simvastatin, the most commonly used statin, can suppress proliferation and migration in NSCLC through caspase-1-mediated pyroptosis.\textsuperscript{132} PPVI, as the main saponin in *Trillium tschonoskii* Maxim, could activate the NF-κB pathway by increasing the generation of ROS, thereby activating the NLRP3 inflammasome. Moreover, PPVI induced an apoptosis-to-pyroptosis switch. Taken together, PPVI could inhibit the progression of NSCLC via pyroptosis.\textsuperscript{133} L61H10 is a heterocyclic ketone derivative, that exerts antitumor effects in NSCLC. L61H10 inhibited NF-κB signaling pathway and induced apoptosis-to-pyroptosis switch to exert anti-tumor effect.\textsuperscript{134} Androgropholide, an active component extracted and purified from *Andrographis paniculata*, which alleviated radiation-induced lung injury by inhibiting AIM2 inflammasome-mediated pyroptosis in macrophages.\textsuperscript{110} Resveratrol could suppress autophagic process and NLRP3 inflammasome activation, thereby alleviated particulate matter-induced lung inflammation and fibrosis.\textsuperscript{153} Lycorine could inhibit NLRP3 inflammasome and pyroptosis by targeting ASC pyrin domain, which exerted anti-fibrotic effect in BLM-induced pulmonary fibrosis.\textsuperscript{24} Scutellarin and Fluorofenidone attenuated
pulmonary fibrosis via inhibiting NLRP3 inflammasome and NF-κB signaling pathway. NAC also alleviated pulmonary fibrosis by inhibiting the activation of NLRP3 inflammasome, but clinical trials have confirmed that it has no significant effect on IPF. Luteolin could regulate the frequency of Tregs and the levels of Treg derived IL-10, which suppressed pyroptosis mediated by caspase-11 in sepsis-induced ALI, thereby alleviated lung injury. Epicatechin (EC), a type of flavonoid, which promoted ubiquitin-mediated Keap1 degradation by upregulating tripartite motif-containing protein 25 expression and enhanced the nuclear localization of Nrf2 protein. Moreover, EC notably inhibited the NLRP3 inflammasome and pyroptosis. Therefore, EC ameliorated cigarette smoke-induced lung inflammation by inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD.

Conclusions
In summary, pyroptosis is a new type of cell death and the executor is the gasdermin family, which is mainly regulated by the caspase-1-mediated canonical and the caspase-4/5/11-mediated noncanonical pathways. The occurrence and progression of pulmonary diseases are related to pyroptosis, and the NLRP3 inflammasome is the most well-studied mechanism. This review highlighted the significance of pyroptosis in the pathogenesis of COPD, asthma, ALI/ARDS, pulmonary fibrosis, lung cancer, and pulmonary infection. The role of pyroptosis as a key target for the treatment of pulmonary diseases has also been highlighted. In addition, we illustrated potential drugs that may become possible therapeutic targets for the management and treatment of respiratory diseases. These studies have revealed that targeting pyroptosis and inflammasomes also plays a role in the treatment of respiratory diseases, providing new ideas for the treatment of respiratory diseases.

At present, the study of pyroptosis is still in its infancy, and many mechanisms are still unclear. For instance, caspase-3/8 play an important role in apoptosis, but recent studies have shown that it is also involved in the process of pyroptosis. Therefore, when and what conditions does the transition between pyroptosis and apoptosis occur? Is pyroptosis an independent mode of cell death, or is it accompanied by other modes of cell death? In addition, there is crosstalk between pyroptosis and necroptosis, what is the mechanism? Such questions still need to be proven by a great deal of studies.

Several agents regulate the pyroptosis pathway. However, studies have largely focused on cancer treatment and autoimmune diseases. Research and development of medicines for the treatment of pulmonary diseases is ongoing. In the future, medicines targeting pyroptosis could be used to treat lung-related diseases. This will provide a better direction for the development of medications for pulmonary-related diseases.

Abbreviations
AIM2, absent in melanoma; ALI, acute lung injury; Ang II, angiotensin; ARDS, acute respiratory distress syndrome; ASC, apoptosis-associated speck like protein containing a caspase recruitment domain; ATP, adenosine triphosphate; BALF, bronchoalveolar lavage fluid; BLM, bleomycin; CARD, caspase recruitment domain; COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; DAMPs, damage-associated molecular patterns; Der f1, Dermatophagoides farina 1; DMF, dimethyl fumarate; GSDMD, gasdermin D; GSDMD-CT, GSDMD C-terminal; GSDMD-NT, GSDMD N-terminal; HMGB1, high mobility group box 1; IFN, interferon; IL, interleukin; IPF, idiopathic pulmonary fibrosis; LncRNA-XIST, long non-coding RNA X-inactive specific transcript; LPS, lipopolysaccharide; LRR, leucine-rich repeat; MyD88, myeloid differentiation primary response 88; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NF-xB, nuclear factor kappa B; NLR, nucleotide-binding oligomerization domain-like receptor; NLRC, NLR family CARD containing proteins; NLRP3, NLR family pyrin domain containing proteins; NOD, nucleotide-binding oligomerization domain; NOX, NADPH oxidase; NSCLC, non-small cell lung cancer; PAMPs, pathogen-associated molecular patterns; PBMCs, peripheral blood mononuclear cells; PRRs, pattern recognition receptors; PYD, pyrin domain; RA-UIP, rheumatoid arthritis-associated–usual interstitial pneumonia; ROS, reactive oxygen species; TBI, traumatic brain injury; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis factor alpha; TRAIL, Toll-like receptor; TREM-1, triggering receptor expressed on myeloid cells; TXNIP, thioredoxin-interacting protein; MAPK, mitogen-activated protein kinase; PLSCR4, Phospholipid scramblase 4; PS, phospholipids.
Author Contributions
TYS and JYL designed the entire subject. JYL, GQF, and NNT: literature collection. TYS and JYL wrote the article. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work

Disclosure
The authors report no conflicts of interest in this work.

References
1. Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113–114. doi:10.1016/S0966-842X(00)01936-3
2. Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18(2):127–136. doi:10.1038/nrm.2016.149
3. Sauer M, Bazan IS, Lee PJ. Cell death in the lung: the apoptosis-necroptosis axis. Annu Rev Physiol. 2019;81:375–402. doi:10.1146/annurev-physiol-020518-114320
4. Vande Walle L, Lamkanfi M. Pyroptosis. Curr Biol. 2016;26(13):R568–R572. doi:10.1016/j.cub.2016.02.019
5. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206–214. doi:10.1111/j.1600-065X.2011.01044.x
6. Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792–800. doi:10.1016/j.cell.2016.03.046
7. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397–411. doi:10.1038/nri3452
8. Diamond CE, Khameneh HJ, Brough D, Mortellaro A. Novel perspectives on non-canonical inflammasome activation. ImmunoTargets Ther. 2015;4:131–141. doi:10.2147/ITTT.S57976
9. Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–665. doi:10.1038/nature15514
10. Broz P, Pelegrín P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2015;15(8):463–477. doi:10.1038/nri3882
11. Deng W, Bai Y, Deng F, et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature. 2014;516(7529):34–38. doi:10.1038/nature13928
12. Zhou Z, He H, Wang K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;370(6525):964–969. doi:10.1126/science.aaz7548
13. Hou J, Zhao R, Xia W, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–1275. doi:10.1038/s41556-020-0755-z
14. Shen X, Wang H, Weng C, Jiang H, Chen J. Caspase 3/GSDME-dependent pyroptosis contributes to chemotherapy drug-induced nephrotoxicity. Cell Death Dis. 2021;12(2):186. doi:10.1038/s41419-021-03458-4
15. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(7):486–511. doi:10.1038/s41418-017-0012-4
16. Han C, Yang Y, Guan Q, et al. New mechanism of nerve injury in Alzheimer’s disease: β-amyloid-induced neuronal pyroptosis. J Cell Mol Med. 2020;24(14):8078–8090. doi:10.1111/jcmm.15439
17. Wu YY, Li KT, Yang HX, et al. Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. J Autoimmun. 2020;106:102336. doi:10.1016/j.jaut.2019.102336
18. Ren S, Deng F, Li L, Xu L, Li X, Fan Q. VX-765 ameliorates renal injury and fibrosis in diabetes by regulating caspase-1-mediated pyroptosis. Cell Death Dis. 2018;9(4):486–505. doi:10.1038/s41419-019-0025-x
19. TsaI YM, Chiang KH, Hung JY, et al. Der f1 induces pyroptosis in human bronchial epithelia via the NLRP3 inflammasome. J Dermatol Sci. 2018;41(2):757–764. doi:10.3892/jds.2017.3310
20. Kim RY, Pinkerton JW, Essilfe AT, et al. Role for NLRP3 inflammasome-mediated, IL-1β-dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med. 2017;196(3):283–297. doi:10.1164/rccm.201609-1830OC
21. Girhimire L, Paudel S, Jin L, Baral P, Cai S, Jeyaseelan C. NLRP6 negatively regulates pulmonary host defense in Gram-positive bacterial infection through modulating neutrophil recruitment and function. PLoS Pathog. 2018;14(9):e1007308. doi:10.1371/journal.ppat.1007308
22. Perlmeier D, de Beer R, Florquin S, van der Poll T, van ‘t Veer C, de Vos AF. Caspase-11 contributes to pulmonary host defense against Klebsiella pneumoniae and local activation of coagulation. Am J Physiol Lung Cell Mol Physiol. 2020;319(1):L105–L114. doi:10.1152/ajlpp.00422.2019
23. Liang Q, Cai W, Zhao Y, et al. Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacol Res. 2020;158:104884. doi:10.1016/j.phrs.2020.104884
24. Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M. Inflammasomes in respiratory disease: from bench to bedside. Chest. 2014;145(5):1121–1133. doi:10.1378/chest.13-1885
25. Barbé F, Douglass T, Saleh M. Advances in Nod-like receptors (NLR) biology. Cytokine Growth Factor Rev. 2014;25(6):681–697.
26. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395–402. doi:10.1038/ni.1864
28. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell.* 2002;10(2):417–426. doi:10.1016/S1097-2765(02)00599-3
29. Fink SL, Bergsbon R, Csinkovski BT. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. *Proc Natl Acad Sci U S A.* 2008;105(11):4312–4317. doi:10.1073/pnas.0707370105
30. Vance RE. The NAIP/NLRC4 inflammasomes. *Curr Opin Immunol.* 2015;32:84–89. doi:10.1016/j.coi.2015.01.010
31. Levy M, Thaiss CA, Zeevi D, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. *Cell.* 2015;163(6):1428–1443. doi:10.1016/j.cell.2015.10.048
32. Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. *Eur J Immunol.* 2018;48(2):230–238. doi:10.1002/eji.201749697
33. Franklin BS, Latz E, Schmidt FI. The intra- and extracellular functions of ASC specks. *Immunity Rev.* 2018;281(1):74–87. doi:10.1111/imr.12611
34. Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. *Nat Rev Drug Discov.* 2019;18(7):698. doi:10.1038/s41573-018-0045-6
35. De Nardo D, De Nardo CM, Latz E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. *Am J Pathol.* 2018;184(1):42–54. doi:10.1016/j.ajpath.2017.01.008
36. Rivers-Auty J, Brough D. Potassium efflux fires the canon: potassium efflux as a common trigger for canonical and noncanonical NLRP3 pathways. *Eur J Immunol.* 2015;45(10):2758–2761. doi:10.1002/eji.201545958
37. He Y, Zeng MY, Yang D, Moto B, Nüühe G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. *Nature.* 2016;530(7590):354–357. doi:10.1038/nature16959
38. Amaral EP, Riteau N, Moayeri M, et al. Lysosomal cathepsin release is required for NLRP3-inflammasome activation by mycobacterium tuberculosis in infected macrophages. *Front Immunol.* 2018;9:1427. doi:10.3389/fimmu.2018.01427
39. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. *Nature.* 2012;481(7361):278–286. doi:10.1038/nature10759
40. Ding J, Shao F. SnapShot: the noncanonical inflammasome. *Science.* 2018;362(6418):1064–1066. doi:10.1126/science.aau2818
41. Rühl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. *Eur J Immunol.* 2015;45(10):2927–2936. doi:10.1002/eji.201545772
42. Yang D, He Y, Muñoz-Planillo R, Liu Q, Nüühe G. Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. *Immunity.* 2015;43(5):923–932. doi:10.1016/j.immuni.2015.10.009
43. Orning P, Weng D, Starheim K, et al. Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. *Science.* 2018;362(6418):1064–1066. doi:10.1126/science.aau2818
44. Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11. *Nature.* 2015;529:354–357. doi:10.1038/nature16959
45. Boucher D, Monteleone M, Coll RC, et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. *Cell Rep.* 2014;8(4):974–982. doi:10.1016/j.celrep.2014.07.012
46. Zeng CY, Li CG, Shu JX, et al. ATP induces caspase-3/gasdermin E-mediated pyroptosis in NLRP3 pathway-blocked murine macrophages. *Apoptosis.* 2019;24(9):703–717. doi:10.1007/s10495-019-01551-x
47. Rogers C, Fernandez-Almenri T, Mayes L, Almenri D, Cingoli G, Almenri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. *Nat Commun.* 2017;8:14128. doi:10.1038/ncomms14128
48. Schwarzer R, Jiao H, Schmidt FI. MLKL- and GSDMD-mediated death of intestinal epithelial cells. *Cell Death Differ.* 2020;27(6):978–993.e976. doi:10.1038/s41418-020-0348-3
49. Jiang S, Gu H, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *J Immunol.* 2019;203(5):1369–1382. doi:10.4049/jimmunol.1900383
50. Fink SL, Bergsbon R, Csinkovski BT. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. *Proc Natl Acad Sci U S A.* 2008;105(11):4312–4317. doi:10.1073/pnas.0707370105
51. Sollberger G, Choidas A, Burn GL, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. *Sci Immunol.* 2018;3(26). doi:10.1126/sciimmunol.aar6889
52. Kambara H, Liu F, Zhang X, et al. Gasdermin D exerts anti-inflammatory effects by promoting neutrophil death. *Cell Rep.* 2018;22(11):2924–2936. doi:10.1016/j.celrep.2018.02.067
53. Wang Y, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *J Immunol.* 2017;199(7):3967–3976. doi:10.7414/S1523-1768(17)-01336-8
54. Zhang JY, Zhou B, Sun RY, et al. The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8. *Cell Res.* 2021;31(10):980–997. doi:10.1042/s41422-021-00506-9
55. Vanaja SK, Russo AJ, Behl B, et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and Caspase-11 activation. *Cell.* 2016;165(5):1106–1119. doi:10.1016/j.cell.2016.04.015
56. Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11. *Nature.* 2011;479(7371):117–121. doi:10.1038/nature10558
62. Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS patients. *Nat Immunol*. 2016;17(10):1176–1186. doi:10.1038/ni.3538
63. Finger JN, Lieb JD, Dare LC, et al. Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity. *J Biol Chem*. 2012;287(30):25303–25307. doi:10.1074/jbc.M112.378323
64. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. *Nat Immunol*. 2015;16(3):229–236. doi:10.1038/ni.3102
65. Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. *Cell*. 2015;160(1–2):62–73. doi:10.1016/j.cell.2014.11.047
66. Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, de Haan JB. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. *Front Physiol*. 2018;9:114. doi:10.3389/fphys.2018.00114
67. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature*. 2006;440(7081):237–241. doi:10.1038/nature04951
68. Hoseini Z, Sepahvand F, Rashidi B, Sahelkar A, Masoudifar A, Mirzaei H. NLRP3 inflammasome: its regulation and involvement in atherosclerosis. *J Cell Physiol*. 2018;233(1):2116–2132. doi:10.1002/jcp.25930
69. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. *Protein Cell*. 2014;5(1):12–20. doi:10.1007/s13238-013-0001-4
70. Rabe KF, Man SM, Kamneganti TD. Inflammasomes and cancer. *Cancer Immunol Res*. 2017;5(2):94–99. doi:10.1158/2326-6066.CIR-16-0269
71. Beckett EL, Stevens RL, Jamiecki AG, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. *J Allergy Clin Immunol*. 2013;131(3):752–762. doi:10.1016/j.jaci.2012.11.053
72. Zhu Z, Lian X, Su X, Wu W, Zeng Y, Chen X. Exosomes derived from adipose-derived stem cells alleviate cigarette smoke-induced lung inflammation and injury by inhibiting alveolar macrophage pyroptosis. *Am J Respir Cell Mol Biol*. 2009;40(4):482–490. doi:10.1155/emb/2009-60380C
73. Churg A, Zhou S, Wang X, Wang R, Wright JL. The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. *Am J Respir Cell Mol Biol*. 2009;40(4):482–490. doi:10.1155/emb/2009-60380C
74. Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. *Nat Immunol*. 2015;16(1):76–77. doi:10.1038/ni.29123
75. Nachmias N, Langier S, Brzezinski RY, et al. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS patients. *Ann Transl Med*. 2019;7(10):237–241. doi:10.21037/atm-20-7983
101. Zheng R, Tao L, Jian H, et al. NLRP3 inflammasome activation and lung fibrosis caused by airborne fine particulate matter.

102. Hindman B, Ma Q. Carbon nanotubes and crystalline silica stimulate robust ROS production, inflammasome activation, and IL-1β secretion in macrophages to induce myofibroblast transformation. *Arch Toxicol*. 2019;93(4):887–907. doi:10.1007/s00204-019-02411-y

103. Stout-Delgado HW, Cho SJ, Chu SG, et al. Age-dependent susceptibility to pulmonary fibrosis is associated with NLRP3 inflammasome activation. *Part Fibre Toxicol*. 2013;10:3. doi:10.1186/1743-8977-10-3

104. Ji J, Hou J, Xia Y, Xiang Z, Han X. NLRP3 inflammasome activation in alveolar epithelial cells promotes myofibroblast differentiation of lung-resident mesenchymal stem cells during pulmonary fibrogenesis. *Biochim Biophys Acta Mol Basis Dis*. 2021;1867(5):166077. doi:10.1016/j.bbadis.2021.166077

106. Sun B, Wang X, Ji Z, et al. NADPH oxidase-dependent NLRP3 inflammasome activation and its important role in lung fibrosis by multiwalled carbon nanotubes. *Small* (Weinheim an der Bergstrasse, Germany). 2015;11(17):2087–2097. doi:10.1002/smll.201402859

108. Meng Y, Pan M, Zheng B, et al. Autophagy attenuates angiotensin II-induced pulmonary fibrosis by inhibiting redox imbalance-mediated NOD-like receptor family pyrin domain containing 3 inflammasome activation. *Antioxid Redox Signal*. 2019;30(4):520–541. doi:10.1089/ars.2017.7261

112. Wang J, Shao Y, Wang W, et al. Caspase-11 deficiency impairs neutrophil recruitment and bacterial clearance in the early stage of pulmonary Klebsiella pneumoniae infection. *Int J Med Microbiol*. 2019;377(8):490–496. doi:10.1016/j.ijmm.2019.07.015

114. Cerqueira DM, Pereira MS, Silva AL, Cunha LD, Zamboni DS. Caspase-1 but not caspase-11 is required for NLRC4-mediated pyroptosis and efferocytosis. *Exp Cell Res*. 2018;364(1):95–103. doi:10.1016/j.yexcr.2018.01.035

117. Cohen TS, Prince AS. Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia. *Oncol Rep*. 2011;24(3–4):312–325. doi:10.1007/s10495-019-01515-1

118. Kerr NA, de Rivera Vaccari JP, Abbassi S, et al. Traumatic brain injury-induced acute lung injury: evidence for activation and inhibition of a neural-respiratory-inflammasome axis. *J Neurotrauma*. 2018;35(17):2067–2076. doi:10.1089/neu.2017.5430

119. Liu et al. 2018;2015-2019;2016-2020;2017-2019;2021. doi:10.1007/s10495-019-01515-1
126. Peng Z, Wang P, Song W, et al. GSDME enhances Cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antimurine immune cytotoxicity. *Signal Transduct Target Ther.* 2020;5(1):159. doi:10.1038/s41392-020-00274-9

127. Xie B, Liu T, Chen S, et al. Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhibition of lung cancer. *Nanoscale.* 2021;13(44):18608–18615. doi:10.1039/D1NR05001J

128. Shi F, Zhang L, Liu X, Wang Y. Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death. *Bioengineered.* 2021;12(1):6332–6342. doi:10.1080/21655979.2021.1971502

129. Liu J, Yao L, Zhang M, Jiang J, Yang M, Wang Y. Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. *Aging.* 2019;11(18):7830–7846. doi:10.18632/aging.102291

130. Xu X, Zhou X, Chen Z, Gao C, Zhao L, Cui Y. Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. *Aging.* 2020;12(6):4711–4726. doi:10.18632/aging.102673

131. Yuan R, Zhao W, Wang QQ, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis. *Pharmacol Res.* 2021;170:105748. doi:10.1016/j.phrs.2021.105748

132. Wang F, Liu W, Ning J, et al. Sinvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. *Int J Biol Sci.* 2018;14(4):406–417. doi:10.7150/ijbs.23542

133. Teng JF, Mei QB, Zhou XG, et al. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer. *Cancers.* 2020;11(12):193. doi:10.3390/cancers11120193

134. Chen L, Weng B, Li H, et al. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch. *Apoptosis.* 2019;24(1–2):74–82. doi:10.1007/s10495-018-1499-y

135. Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ. A small molecule inhibitor of Caspase 1. In: *Probe Reports from the NIH Molecular Libraries Program.* Bethesda (MD): National Center for Biotechnology Information (US); 2010.

136. Rudolph K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. *Osteoarthrits Cartilage.* 2003;11(10):738–746. doi:10.1016/S1063-4584(03)00153-5

137. Wannamaker W, Davies R, Namechuk M, et al. (S)-1-[(4-aminomethyl)-phenyl]-methanoyl]–amino]-3,3-dimethyl-butanoyl]-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. *J Pharmacol Exp Ther.* 2007;321(2):509–516. doi:10.1124/jpet.106.111344

138. Flores J, Noël A, Foveau B, Lynam J, Lexcur C, LeBlanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model. *Nat Commun.* 2018;9(1):3916. doi:10.1038/s41467-018-06449-x

139. Audia JP, Yang XM, Crockett ES, et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y(12) receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. *Basic Res Cardiol.* 2018;113(5):32. doi:10.1007/s00395-018-0692-2

140. Siewmund B, Zeitz M. Pralnacasan (vertex pharmaceuticals). *IDrugs.* 2003;6(2):154–158.

141. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis *C.* *Hepatology.* 2007;46(2):324–329. doi:10.1002/hep.21664

142. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. *Curr Opin Drug Discov Devel.* 2010;13(5):568–576.

143. Coll RC, Robertson AA, Chae JI, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. *Nat Med.* 2015;21(3):248–255. doi:10.1038/nm.3806

144. Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. *Nat Chem Biol.* 2019;15(6):556–559. doi:10.1038/s41589-019-0277-7

145. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. *J Cell Biol.* 2009;187(1):61–70. doi:10.1083/jcb.200903124

146. Desu H, Plastini M, Illiano P, et al. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis. *J Neuroinflammation.* 2017;14(1):130. doi:10.1186/s12974-020-01826-0

147. Tapia VS, Daniels MJD, Palazón-Riquelme P, et al. The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes. *Cell Death Biol.* 2016;23(7):1219–1231. doi:10.1038/cdd.2015.176

148. de Vasconcelos NM, Van Odenbosch N, Van Gorp H, Parthoens E, Lamkanfi M. Single-cell analysis of pyroptosis dynamics reveals conserved GSDMD-mediated subcellular events that precede plasma membrane rupture. *Cell Death Differ.* 2019;26(1):146–161. doi:10.1038/s41418-018-0106-7

149. Rathkey JK, Zhao J, Liu Z, et al. Chemical disruption of the pyrototic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. *Sci Immunol.* 2018;3(26). doi:10.1126/sciimmunol.aat2738

150. Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, et al. Succinination inactivates gasdermin D and blocks pyroptosis. *Science.* 2020;369(6511):1633–1637. doi:10.1126/science.abb9818

151. Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, et al. Succinination inactivates gasdermin D and blocks pyroptosis. *Science.* 2020;369(6511):1633–1637. doi:10.1126/science.abb9818

152. Martín-Sánchez F, Diamond C, Zeitler M, et al. Inflammasome-dependent IL-1β release depends upon membrane permeabilisation. *Cell Death Differ.* 2016;23(7):1219–1231. doi:10.1038/cdd.2015.176

153. Ding S, Wang H, Wang M, Bai L, Yu P, Wu W. Resveratrol alleviates chronic “real-world” ambient particulate matter-induced lung inflammation and fibrosis by inhibiting NLRP3 inflammasome activation in mice. *Ecotoxicol Environ Saf.* 2019;182:109425. doi:10.1016/j.ecoenv.2019.109425
154. Peng L, Wen L, Shi QF, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. *Cell Death Dis.* 2020;11(11):978. doi:10.1038/s41419-020-03178-2

155. Song C, He L, Zhang J, et al. Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1β/IL-1R1/MyD88/NF-κB pathway. *J Cell Mol Med.* 2016;20(11):2064–2077. doi:10.1111/jcmm.12898

156. Zhang ZT, Zhang DY, Xie K, Wang CJ, Xu F. Luteolin activates Tregs to promote IL-10 expression and alleviating caspase-11-dependent pyroptosis in sepsis-induced lung injury. *Int Immunopharmacol.* 2021;99:107914. doi:10.1016/j.intimp.2021.107914